Navigation Links
Stimatix GI Reports Encouraging Interim Results

MISGAV, Israel, May 3, 2010 /PRNewswire/ --

- The Company is Developing an Artificial Sphincter (the AOS-C1000) to Provide Bowel Control and Prevent Clinical Complications for People With Stomas.

Stimatix GI, located in the Misgav Venture Accelerator, has reported encouraging interim results in its animal trials of the AOS-C1000 artificial sphincter, designed to provide stoma patients with a new means of bowel control.

The interim results demonstrate that the AOS-C1000 artificial sphincter can restore voluntary control to people with stoma.

A stoma is the result of a surgical procedure that diverts the end of the bowel to an artificial opening ("stoma") in the abdominal wall. Bowel content and intestinal gases exit through the stoma. People with stoma lose the ability to control elimination and the contents of the bowel spill out uncontrollably. Consequently, a collection bag is always attached to the stoma.

There are many side-effects of using such a bag, including a significant change in lifestyle, an impact on self-image, problems reintegrating into society, unpleasant odors, leaks, and intrusive bowel noises. Additional clinical complications may arise in the long term, including severe skin rashes around the stoma and parastomal hernia.

Stimatix's artificial sphincter, the AOS-C1000, restores patients' control over the human elimination function. The sphincter is installed in a simple procedure during the creation of the stoma (or in a separate surgical procedure for those who already have a stoma).

The artificial sphincter, discreet and aesthetic, can significantly improve quality of life of stoma patients, while greatly reducing potential clinical complications.

According to David Hanuka, CEO of Stimatix GI, "The AOS-C1000 has the potential to improve the lives of stoma patients. Despite vast resources that have been invested over the last 50 years, no complete solution is available for patients whose quality of life and self-image are impaired. The interim results of the trial encourage us to continue developing the device to achieve the desired breakthrough."

About Stimatix GI

Stimatix GI ( is a life-science startup that is developing an innovative artificial sphincter for stoma patients.

The current state of the art is based on techniques devised during the last 50 years which rely on an external pouch that collects bowel contents.

The current annual world market for stoma pouches is estimated at $2 billion.

    Stimatix GI seeks to improve quality of life with the AOS-C1000 for
people with stoma.

    David Hanuka, CEO
    Stimatix GI Ltd.
    T +972-72-260-7084

SOURCE Stimatix GI Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
2. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
3. Capstone Reports Additional High Grade Copper-Gold Results From Minto East
4. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
6. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
7. APC Group, Inc. Reports Fiscal Year End Sales Revenues Increased 30% for 2009
8. NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results
9. Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
10. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
11. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
Post Your Comments:
(Date:11/26/2015)... , Nederland, November 26, 2015 /PRNewswire/ ... --> Een nieuwe aanpak combineert immunotherapie ... gevorderde kanker. ) ... -->      (Photo: ... het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... As part of a global movement to ... together who want to combine talents and resources to help create sustainable communities ... The non-profit launched its first major fundraiser on November 6, 2015 at Bent ...
(Date:11/25/2015)... NV (PRWEB) , ... November 25, 2015 , ... Dr. ... patients to learn more about hair loss treatment with the Capillus272™ Pro laser therapy ... effective solution for thicker and fuller hair, without the need for surgery, prescription pills, ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... people across the country to celebrate their sobriety and show through pictures what ... “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by ... Chicago, IL, UV Angel is evaluating the efficacy of its product and its disinfection ... (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic ...
Breaking Medicine News(10 mins):